Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Default

Display 15 Products per page

Ibrance
Read More
Ibrance (palbociclib; Pfizer) is a small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). When associated with cyclin-D proteins, CDK4/6 are able to phosphorylate and inactivate.
February 4, 2016
Find out more
Follicular Lymphoma KOL Interview

$599.00

“When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”
February 3, 2016
Find out more
Faslodex
Read More
Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).
February 2, 2016
Find out more
MF-59 adjuvanted QIV
Read More
CSL’s MF-59 adjuvanted QIV is a subunit, surface antigen-containing seasonal QIV adjuvanted withMF59. It contains antigens from two A strains and two B strains specified by the World HealthOrganization seasonally for seasonal influenza vaccination.
February 2, 2016
Find out more
VLP QIV
Read More
Novavax’s virus-like particle (VLP) quadrivalent influenza vaccine (QIV), currently in Phase II

development, has the potential for significant market success if it is able to demonstrate superior

safety or efficacy data in Phase III studies.
February 2, 2016
Find out more
Drug Pricing and Market Access KOL Interview

$599.00

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.
February 1, 2016
Find out more
Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.
January 26, 2016
Find out more
Ampyra
Read More
Ampyra is a potassium channel blocker, marketed by Acorda Therapeutics and Biogen, which is

approved to improve walking ability in multiple sclerosis patients. Although Ampyra’s active molecule

fampridine (4-aminopyridine) is readily available, by using Elan’s Intestinal Protective Drug Absorption

System, Acorda has developed a sustained-released oral tablet formulation allowing twice-daily

dosing.
January 26, 2016
Find out more
Zaltrap
Read More
Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2
and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).
January 19, 2016
Find out more
Intersection Between Tech and Pharma KOL Interview

$599.00

Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.
January 12, 2016
Find out more
Asia-Pacific Disease Incidence and Prevalence

$5,250.00

The Asia-Pacific (APAC) region is a part of the world which includes several developing and developed countries. Countries covered in this report include Australia, China, India, Japan, Malaysia, South Korea, Thailand, and Vietnam.
January 1, 2016
Find out more
Peretinoin
Read More
Peretinoin (Kowa/Chugai Pharmaceutical) is a synthetic acyclic retinoid inhibitor of transforming growth factor alpha (TGF-alpha) and platelet-derived growth factor receptor (PDGFR). TGF-alpha induces epithelial development, and is closely involved in hepatocarcinogenesis.
December 31, 2015
Find out more
Tivantinib
Read More
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
December 31, 2015
Find out more
F/TAF
Read More
F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).
December 11, 2015
Find out more
D/C/F/TAF
Read More
D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…
December 11, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *